Long-Term NIH Grants Raise Doubts

WASHINGTON—Recent increases in the number and type of longterm grants from the National Institutes of Health may intensify competition between new awards and grants continued from previous years. But officials say the self-limiting nature of the new longterm grants and new institute controls should prevent problems that forced elimination of seven-year awards in the 1970s. “In any given year, about 85 percent of the NIH budget is a commitment [to grants] from previous years,”

Written byRon Cowen
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

WASHINGTON—Recent increases in the number and type of longterm grants from the National Institutes of Health may intensify competition between new awards and grants continued from previous years. But officials say the self-limiting nature of the new longterm grants and new institute controls should prevent problems that forced elimination of seven-year awards in the 1970s.

“In any given year, about 85 percent of the NIH budget is a commitment [to grants] from previous years,” noted Norman Mansfield, director of the NIH division of finance management. The balance between funding new grants and continuing support for grants in their third, fourth or fifth year is “a delicate tradeoff,” he said.

According to William Goldwater, director of NIH’s extramural programs management office, the White House Office of Management and Budget is concerned about a growing commitment for continuing grants. He said such concerns explain “why NIH is very discreet” in its small ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies